ReP USP - Resultado da busca

Artigo de periodico
Association between cigarette smoking and subclinical markers of cardiovascular harm (2025)
Yao, Zhiqi; Tasdighi, Erfan; Dardari, Zeina A; Jha, Kunal K; Osuji, Ngozi; Rajan, Tanuja; Boakye, Ellen; Rodriguez, Carlos J.; Lotufo, Paulo Andrade ; Benseñor, Isabela Judith Martins
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: FATORES DE RISCO, TABAGISMO, BIOMARCADORES, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
YAO, Zhiqi et al. Association between cigarette smoking and subclinical markers of cardiovascular harm. Journal of the american college of cardiology, v. 85, n. 10, p. 1018-1034, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/84754. Acesso em: 02 nov. 2025.
APA
Yao, Z., Tasdighi, E., Dardari, Z. A., Jha, K. K., Osuji, N., Rajan, T., et al. (2025). Association between cigarette smoking and subclinical markers of cardiovascular harm. Journal of the american college of cardiology, 85( 10), 1018-1034. doi:10.1016/j.jacc.2024.12.032
NLM
Yao Z, Tasdighi E, Dardari ZA, Jha KK, Osuji N, Rajan T, Boakye E, Rodriguez CJ, Lotufo PA, Benseñor IJM. Association between cigarette smoking and subclinical markers of cardiovascular harm [Internet]. Journal of the american college of cardiology. 2025 ; 85( 10): 1018-1034.[citado 2025 nov. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84754
Vancouver
Yao Z, Tasdighi E, Dardari ZA, Jha KK, Osuji N, Rajan T, Boakye E, Rodriguez CJ, Lotufo PA, Benseñor IJM. Association between cigarette smoking and subclinical markers of cardiovascular harm [Internet]. Journal of the american college of cardiology. 2025 ; 85( 10): 1018-1034.[citado 2025 nov. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84754
Artigo de periodico
The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? (2022)
Bocchi, Edimar Alcides ; Lima, Ivna Girard Cunha Vieira
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: RESULTADO DE TRATAMENTO, INSUFICIÊNCIA CARDÍACA, FÁRMACOS SINTÉTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCHI, Edimar Alcides e LIMA, Ivna Girard Cunha Vieira. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis?. Journal of the american college of cardiology, v. 80, n. 6, p. 595-597, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50443. Acesso em: 02 nov. 2025.
APA
Bocchi, E. A., & Lima, I. G. C. V. (2022). The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? Journal of the american college of cardiology, 80( 6), 595-597. doi:10.1016/j.jacc.2022.05.028
NLM
Bocchi EA, Lima IGCV. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? [Internet]. Journal of the american college of cardiology. 2022 ; 80( 6): 595-597.[citado 2025 nov. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50443
Vancouver
Bocchi EA, Lima IGCV. The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy Quo Vadis? [Internet]. Journal of the american college of cardiology. 2022 ; 80( 6): 595-597.[citado 2025 nov. 02 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50443
Artigo de periodico
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia (2020)
Santos Filho, Raul Dias dos ; Stein, Evan A.; Hovingh, G. Kees; Blom, Dirk J; Soran, Handrean; Watts, Gerald F; Lopez, J. Antonio G; Bray, Sarah; Kurtz, Christopher E; Hamer, Andrew W
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS, ANTIMETABÓLITOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS FILHO, Raul Dias dos et al. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 75, n. 6, p. 565-574, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.12.020. Acesso em: 02 nov. 2025.
APA
Santos Filho, R. D. dos, Stein, E. A., Hovingh, G. K., Blom, D. J., Soran, H., Watts, G. F., et al. (2020). Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. Journal of the american college of cardiology, 75( 6), 565-574. doi:10.1016/j.jacc.2019.12.020
NLM
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Vancouver
Santos Filho RD dos, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, Lopez JAG, Bray S, Kurtz CE, Hamer AW. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2020 ; 75( 6): 565-574.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.12.020
Artigo de periodico
Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study (2020)
Boccara, Franck; Kumar, Princy N; Caramelli, Bruno ; Calmy, Alexandra; Lopez, J. Antonio G; Bray, Sarah; Cyrille, Marcoli; Rosenson, Robert S
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ESTATINAS, COLESTEROL, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS, DISLIPIDEMIAS, HIV
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCARA, Franck et al. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study. Journal of the american college of cardiology, v. 75, n. 20, p. 2570-2584, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2020.03.025. Acesso em: 02 nov. 2025.
APA
Boccara, F., Kumar, P. N., Caramelli, B., Calmy, A., Lopez, J. A. G., Bray, S., et al. (2020). Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study. Journal of the american college of cardiology, 75( 20), 2570-2584. doi:10.1016/j.jacc.2020.03.025
NLM
Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study [Internet]. Journal of the american college of cardiology. 2020 ; 75( 20): 2570-2584.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2020.03.025
Vancouver
Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study [Internet]. Journal of the american college of cardiology. 2020 ; 75( 20): 2570-2584.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2020.03.025
Artigo de periodico
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome (2020)
Bittner, Vera A; Szarek, Michael; Aylward, Philip E; Bhatt, Deepak L; Diaz, Rafael; Edelberg, Jay M; Fras, Zlatko; Goodman, Shaun G; Halvorsen, Sigrun; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, LIPOPROTEÍNAS, ENZIMAS PROTEOLÍTICAS, LIPOPROTEÍNAS LDL, ESTATINAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BITTNER, Vera A et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the american college of cardiology, v. 75, n. 2, p. 133-144, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.10.057. Acesso em: 02 nov. 2025.
APA
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., et al. (2020). Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the american college of cardiology, 75( 2), 133-144. doi:10.1016/j.jacc.2019.10.057
NLM
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Nicolau JC. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome [Internet]. Journal of the american college of cardiology. 2020 ; 75( 2): 133-144.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.10.057
Vancouver
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Nicolau JC. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome [Internet]. Journal of the american college of cardiology. 2020 ; 75( 2): 133-144.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.10.057
Artigo de periodico
Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography (2020)
Furtado, Remo H. M; Nicolau, José Carlos ; Guo, Jianping; Im, Kyungah; White, Jennifer A; Sabatine, Marc S; Newby, L. Kristin; Giugliano, Robert P
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, MORFINA, ANGIOGRAFIA, DOENÇAS CARDIOVASCULARES, AGREGAÇÃO PLAQUETÁRIA, INTERAÇÃO DE MEDICAMENTOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Journal of the american college of cardiology, v. 75, n. 3, p. 289-300, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.11.035. Acesso em: 02 nov. 2025.
APA
Furtado, R. H. M., Nicolau, J. C., Guo, J., Im, K., White, J. A., Sabatine, M. S., et al. (2020). Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. Journal of the american college of cardiology, 75( 3), 289-300. doi:10.1016/j.jacc.2019.11.035
NLM
Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography [Internet]. Journal of the american college of cardiology. 2020 ; 75( 3): 289-300.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.11.035
Vancouver
Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography [Internet]. Journal of the american college of cardiology. 2020 ; 75( 3): 289-300.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.11.035
Artigo de periodico
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery (2019)
Goodman, Shaun G; Aylward, Philip E; Szarek, Michael; Chumburidze, Vakhtang; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Edelberg, Jay M; Hanotin, Corinne; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DOENÇAS CARDIOVASCULARES, REVASCULARIZAÇÃO MIOCÁRDICA, COMPLICAÇÕES PÓS-OPERATÓRIAS, ANTICORPOS MONOCLONAIS, ENZIMAS PROTEOLÍTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOODMAN, Shaun G et al. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the american college of cardiology, v. 74, n. 9, p. 1177-1186, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.07.015. Acesso em: 02 nov. 2025.
APA
Goodman, S. G., Aylward, P. E., Szarek, M., Chumburidze, V., Bhatt, D. L., Bittner, V. A., et al. (2019). Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the american college of cardiology, 74( 9), 1177-1186. doi:10.1016/j.jacc.2019.07.015
NLM
Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Nicolau JC. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1177-1186.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.07.015
Vancouver
Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Nicolau JC. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1177-1186.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.07.015
Artigo de periodico
Sonothrombolysis in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (2019)
Mathias Junior, Wilson; Tsutsui, Jeane M; Tavares, Bruno G; Fava, Agostina M; Aguiar, Miguel O. D; Borges, Bruno C; Oliveira Junior, Mucio T.; Soeiro, Alexandre; Nicolau, José Carlos; Ramires, José Antônio Franchini; Kalil Filho, Roberto
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, PROCEDIMENTOS CIRÚRGICOS CARDIOVASCULARES, ULTRASSONOGRAFIA, ECOCARDIOGRAFIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATHIAS JUNIOR, Wilson et al. Sonothrombolysis in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Journal of the american college of cardiology, v. 73, n. 22, p. 2832-2842, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.03.006. Acesso em: 02 nov. 2025.
APA
Mathias Junior, W., Tsutsui, J. M., Tavares, B. G., Fava, A. M., Aguiar, M. O. D., Borges, B. C., et al. (2019). Sonothrombolysis in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Journal of the american college of cardiology, 73( 22), 2832-2842. doi:10.1016/j.jacc.2019.03.006
NLM
Mathias Junior W, Tsutsui JM, Tavares BG, Fava AM, Aguiar MOD, Borges BC, Oliveira Junior MT, Soeiro A, Nicolau JC, Ramires JAF, Kalil Filho R. Sonothrombolysis in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention [Internet]. Journal of the american college of cardiology. 2019 ; 73( 22): 2832-2842.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.006
Vancouver
Mathias Junior W, Tsutsui JM, Tavares BG, Fava AM, Aguiar MOD, Borges BC, Oliveira Junior MT, Soeiro A, Nicolau JC, Ramires JAF, Kalil Filho R. Sonothrombolysis in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention [Internet]. Journal of the american college of cardiology. 2019 ; 73( 22): 2832-2842.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.006
Artigo de periodico
Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial (2019)
Jukema, J. Wouter; Szarek, Michael; Zijlstra, Laurien E; Silva, H. Asita de; Bhatt, Deepak L; Bittner, Vera A; Diaz, Rafael; Edelberg, Jay M; Goodman, Shaun G; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, ARTERIOSCLEROSE, ANTICORPOS MONOCLONAIS, DISLIPIDEMIAS, ESTATINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JUKEMA, J. Wouter et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, v. 74, n. 9, p. 1167-1176, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.03.013. Acesso em: 02 nov. 2025.
APA
Jukema, J. W., Szarek, M., Zijlstra, L. E., Silva, H. A. de, Bhatt, D. L., Bittner, V. A., et al. (2019). Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, 74( 9), 1167-1176. doi:10.1016/j.jacc.2019.03.013
NLM
Jukema JW, Szarek M, Zijlstra LE, Silva HA de, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1167-1176.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.013
Vancouver
Jukema JW, Szarek M, Zijlstra LE, Silva HA de, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 74( 9): 1167-1176.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.013
Artigo de periodico
Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study (2019)
Farkouh, Michael E; Domanski, Michael; Dangas, George D; Godoy, Lucas C; Mack, Michael J; Siami, Flora S; Hamza, Taye H; Shah, Binita; Stefanini, Giulio G; Sidhu, Mandeep S; Hueb, Whady Armindo
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: REVASCULARIZAÇÃO MIOCÁRDICA, SOBREVIDA, DIABETES MELLITUS, CORONARIOPATIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FARKOUH, Michael E et al. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study. Journal of the american college of cardiology, v. 73, n. 6, p. 629-638, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.11.001. Acesso em: 02 nov. 2025.
APA
Farkouh, M. E., Domanski, M., Dangas, G. D., Godoy, L. C., Mack, M. J., Siami, F. S., et al. (2019). Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study. Journal of the american college of cardiology, 73( 6), 629-638. doi:10.1016/j.jacc.2018.11.001
NLM
Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B, Stefanini GG, Sidhu MS, Hueb WA. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study [Internet]. Journal of the american college of cardiology. 2019 ; 73( 6): 629-638.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.001
Vancouver
Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B, Stefanini GG, Sidhu MS, Hueb WA. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study [Internet]. Journal of the american college of cardiology. 2019 ; 73( 6): 629-638.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.001
Artigo de periodico
Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial (2019)
Berwanger, Otavio; Lopes, Renato D; Moia, Diogo D. F; Fonseca, Francisco A; Jiang, Lixin; Goodman, Shaun G; Nicholls, Stephen J; Parkhomenko, Alexander; Averkov, Oleg; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: FIBRINÓLISE, AGREGAÇÃO PLAQUETÁRIA, INFARTO DO MIOCÁRDIO, DOENÇAS CARDIOVASCULARES, ACIDENTE VASCULAR CEREBRAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERWANGER, Otavio et al. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial. Journal of the american college of cardiology, v. 73, n. 22, p. 2819-2828, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.03.011. Acesso em: 02 nov. 2025.
APA
Berwanger, O., Lopes, R. D., Moia, D. D. F., Fonseca, F. A., Jiang, L., Goodman, S. G., et al. (2019). Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial. Journal of the american college of cardiology, 73( 22), 2819-2828. doi:10.1016/j.jacc.2019.03.011
NLM
Berwanger O, Lopes RD, Moia DDF, Fonseca FA, Jiang L, Goodman SG, Nicholls SJ, Parkhomenko A, Averkov O, Nicolau JC. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 22): 2819-2828.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.011
Vancouver
Berwanger O, Lopes RD, Moia DDF, Fonseca FA, Jiang L, Goodman SG, Nicholls SJ, Parkhomenko A, Averkov O, Nicolau JC. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 22): 2819-2828.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2019.03.011
Artigo de periodico-carta/editorial
The globalization of health information in different languages new frontier with JACC Portuguese [Editorial] (2019)
Bocchi, Edimar Alcides
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: GLOBALIZAÇÃO, INFORMAÇÃO EM SAÚDE, LÍNGUA PORTUGUESA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCHI, Edimar Alcides. The globalization of health information in different languages new frontier with JACC Portuguese [Editorial]. Journal of the american college of cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jacc.2018.11.021. Acesso em: 02 nov. 2025. , 2019
APA
Bocchi, E. A. (2019). The globalization of health information in different languages new frontier with JACC Portuguese [Editorial]. Journal of the american college of cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.jacc.2018.11.021
NLM
Bocchi EA. The globalization of health information in different languages new frontier with JACC Portuguese [Editorial] [Internet]. Journal of the american college of cardiology. 2019 ; 73( 3): 375-377.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.021
Vancouver
Bocchi EA. The globalization of health information in different languages new frontier with JACC Portuguese [Editorial] [Internet]. Journal of the american college of cardiology. 2019 ; 73( 3): 375-377.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.021
Artigo de periodico
Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial (2019)
Szarek, Michael; White, Harvey D; Schwartz, Gregory G; Alings, Marco; Bhatt, Deepak L; Bittner, Vera A; Chiang, Chern-En; Diaz, Rafael; Edelberg, Jay M; Nicolau, José Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES, SÍNDROME CORONARIANA AGUDA, ESTATINAS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SZAREK, Michael et al. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, v. 73, n. 4, p. 387-396, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.10.039. Acesso em: 02 nov. 2025.
APA
Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial. Journal of the american college of cardiology, 73( 4), 387-396. doi:10.1016/j.jacc.2018.10.039
NLM
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039
Vancouver
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Nicolau JC. Alirocumab reduces total nonfatal cardiovascular and fatal events the ODYSSEY OUTCOMES trial [Internet]. Journal of the american college of cardiology. 2019 ; 73( 4): 387-396.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.10.039
Artigo de periodico-carta/editorial
REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability (2018)
Avila, Monica Samuel; Bocchi, Edimar Alcides; Ferreira, Silvia Moreira Ayub
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERTENSÃO, EVENTO ADVERSO A MEDICAMENTO, TOXICOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AVILA, Monica Samuel e BOCCHI, Edimar Alcides e FERREIRA, Silvia Moreira Ayub. REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability. Journal of the american college of cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.jacc.2018.07.003. Acesso em: 02 nov. 2025. , 2018
APA
Avila, M. S., Bocchi, E. A., & Ferreira, S. M. A. (2018). REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability. Journal of the american college of cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.jacc.2018.07.003
NLM
Avila MS, Bocchi EA, Ferreira SMA. REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability [Internet]. Journal of the american college of cardiology. 2018 ; 72( 10): 1182-1183.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.003
Vancouver
Avila MS, Bocchi EA, Ferreira SMA. REPLY [Carta]: can carvedilol prevent chemotherapy-related cardiotoxicity? A dream to be balanced with tolerability [Internet]. Journal of the american college of cardiology. 2018 ; 72( 10): 1182-1183.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.003
Artigo de periodico
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (2018)
Everett, Brendan M.; Nicolau, Jose C.; DONATH, Marc Y.; PRADHAN, Aruna D.; THUREN, Tom; PAIS, Prem; GLYNN, Robert J; LIBBY, Peter; RIDKER, Paul M.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 02 nov. 2025.
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Artigo de periodico
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis (2018)
Tsimikas, Sotirios; Santos Filho, Raul Dias dos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ESTENOSE DA VALVA AÓRTICA, FATORES DE RISCO, DOENÇAS CARDIOVASCULARES, LIPOPROTEÍNAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TSIMIKAS, Sotirios e SANTOS FILHO, Raul Dias dos. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the american college of cardiology, v. 71, n. 2, p. 177-192, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2017.11.014. Acesso em: 02 nov. 2025.
APA
Tsimikas, S., & Santos Filho, R. D. dos. (2018). NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the american college of cardiology, 71( 2), 177-192. doi:10.1016/j.jacc.2017.11.014
NLM
Tsimikas S, Santos Filho RD dos. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis [Internet]. Journal of the american college of cardiology. 2018 ; 71( 2): 177-192.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2017.11.014
Vancouver
Tsimikas S, Santos Filho RD dos. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis [Internet]. Journal of the american college of cardiology. 2018 ; 71( 2): 177-192.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2017.11.014
Artigo de periodico
Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial (2018)
Corbalan, Ramon; Nicolau, Jose Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTICOAGULANTES, FIBRILAÇÃO ATRIAL, ACIDENTE VASCULAR CEREBRAL, AMÉRICA LATINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CORBALAN, Ramon e NICOLAU, Jose Carlos. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, v. 72, n. 13, p. 1466-1475, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.07.037. Acesso em: 02 nov. 2025.
APA
Corbalan, R., & Nicolau, J. C. (2018). Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, 72( 13), 1466-1475. doi:10.1016/j.jacc.2018.07.037
NLM
Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
Vancouver
Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
Artigo de periodico
Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy (2018)
Senra, Tiago; Ianni, Barbara M; Costa, Ana C. P; Mady, Charles; Martinelli-Filho, Martino; Kalil-Filho, Roberto; Rochitte, Carlos E.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: MIOCARDIOPATIA CHAGÁSICA, PROGNÓSTICO, MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SENRA, Tiago et al. Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy. Journal of the american college of cardiology, v. 72, n. 21, p. 2577-2587, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.08.2195. Acesso em: 02 nov. 2025.
APA
Senra, T., Ianni, B. M., Costa, A. C. P., Mady, C., Martinelli-Filho, M., Kalil-Filho, R., & Rochitte, C. E. (2018). Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy. Journal of the american college of cardiology, 72( 21), 2577-2587. doi:10.1016/j.jacc.2018.08.2195
NLM
Senra T, Ianni BM, Costa ACP, Mady C, Martinelli-Filho M, Kalil-Filho R, Rochitte CE. Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy [Internet]. Journal of the american college of cardiology. 2018 ; 72( 21): 2577-2587.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.08.2195
Vancouver
Senra T, Ianni BM, Costa ACP, Mady C, Martinelli-Filho M, Kalil-Filho R, Rochitte CE. Long-term prognostic value of myocardial fibrosis in patients with Chagas cardiomyopathy [Internet]. Journal of the american college of cardiology. 2018 ; 72( 21): 2577-2587.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.08.2195
Artigo de periodico
Clinical Genetic Testing for Familial Hypercholesterolemia (2018)
Sturm, Amy C.; Santos, Raul D.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, DOENÇAS CARDIOVASCULARES, COLESTEROL, CUSTOS DOS CUIDADOS DE SAÚDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STURM, Amy C. e SANTOS, Raul D. Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 72, n. 6, p. 662-680, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.05.044. Acesso em: 02 nov. 2025.
APA
Sturm, A. C., & Santos, R. D. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, 72( 6), 662-680. doi:10.1016/j.jacc.2018.05.044
NLM
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Vancouver
Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
Artigo de periodico
Pulmonary arterialhHypertension-related morbidity is prognostic for mortality (2018)
Mclaughlin, Vallerie V.; Souza, Rogerio
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR, MORBIDADE, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MCLAUGHLIN, Vallerie V. e SOUZA, Rogerio. Pulmonary arterialhHypertension-related morbidity is prognostic for mortality. Journal of the american college of cardiology, v. 71, n. 7, p. 752-763, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2017.12.010. Acesso em: 02 nov. 2025.
APA
Mclaughlin, V. V., & Souza, R. (2018). Pulmonary arterialhHypertension-related morbidity is prognostic for mortality. Journal of the american college of cardiology, 71( 7), 752-763. doi:10.1016/j.jacc.2017.12.010
NLM
Mclaughlin VV, Souza R. Pulmonary arterialhHypertension-related morbidity is prognostic for mortality [Internet]. Journal of the american college of cardiology. 2018 ; 71( 7): 752-763.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2017.12.010
Vancouver
Mclaughlin VV, Souza R. Pulmonary arterialhHypertension-related morbidity is prognostic for mortality [Internet]. Journal of the american college of cardiology. 2018 ; 71( 7): 752-763.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.jacc.2017.12.010

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Funding Agencies